Indicadores de reserva ovariana em mulheres com lúpus eritematoso sistêmico

• Ano de defesa: 2011
• Autor(a) principal: Olivio Brito Malheiro
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais
• Palavras-chave em Português: Lúpus eritematoso; Hormônio anti-mülleriano; Hormônio folículo estimulante; Ovário; Medicina; Lupus eritematoso sistêmico; Insuficiência ovariana primária; Hormônio anti-mulleriano; Contagem de folículos antrais; Lúpus eritematoso sistêmico; Reserva ovariana
• Link de acesso: https://hdl.handle.net/1843/BUOS-9PBJWJ

Background: Systemic lupus erythematosus (SLE) is a multisystem disease, which affects mostly women at your reproductive age, and can promote premature ovarian dysfunction related to factors associated to rheumatic disease or its treatment. The assessment of indicators of ovarian reserve can determine if there are differences between these patients and the general population, prior to the establishment of the climacteric. Objective: The aim of this study was to evaluate if there are differences in ovarian reserve markers in systemic lupus erythematosus (SLE) patients compared to controls, and explore the relationship of such markers with clinical and treatment features of SLE patients. Methods: This was a controlled cross-sectional study including 27 women with SLE and 27 controls. All participants were between 18 and 40 years, were eumenorrheic and did not use hormone therapy or hormone contraceptives in the past 6 months. Clinical data were assessed at a regular follow up visit, serum concentrations of follicle stimulating hormone (FSH) and anti-mullerian hormone (AMH), and through transvaginal ultrasound antral follicle count were assessed at early follicular phase of a subsequent menstrual cycle. Results: We found no difference between SLE group and control group at analysis of AFC [median (interquartile interval) 7 (5 13) vs. 11 (7 12), p=0.076], FSH [6.44 (4.19 7.69) vs. 7.5 (6.03 8.09) mUI/ml, p=0.135] and AMH levels [1.23 (0.24 4.63) ng/ml vs. 1.52 (1.33 1.88) ng/ml, p=0.684]. However, AMH values in SLE group were more heterogeneous compared to control group. The presence of nephritis and the cumulative dose of cyclophosphamide were factors individually related to reduced ovarian reserve, by association with lower values of AFC and AMH. At multivariate logistic regression, control group was more likely to have higher AMH values than the SLE (OR 5.2, 95% CI 1.286 - 20.405, p=0.021) and in the SLE group, AMH was associated with lower maximum corticosteroid doses in the followup (OR 0.95, 95%CI 0.894-1.000, p=0.50). AFC was associated with lower scores of SLICC/ACR-DI (OR: 0.14, 95% CI 0.025-0.841, p=0.031). Conclusion: SLE patients who were eumenorrheic had average values of ovarian reserve markers similar to controls. However, AMH had a larger variation in that group, needing evaluation of other markers to clarify the best clinical application for it. Ovarian function is more compromised in patients with nephritis, higher cumulated dose of cyclophosphamide and with higher disease damage scores.